Chemical inhibition of Wip1 phosphatase contributes to suppression of tumorigenesis

Wip1 is an amplified oncogene whose deletion causes a tumor resistant phenotype in mice. These observations provide justification for a search for Wip1 chemical inhibitors as potential anticancer drugs. Here we report a group of Wip1 inhibitors with anticancer properties both in vitro and in vivo. In vitro, inactivation of Wip1 reduces the proliferation rate of breast cancer cell lines and enhances growth inhibition caused by doxorubicin. In vivo, administration of Wip1 inhibitors decreases proliferation of xenograph tumors and tumors developed in MMTV-c-Neu transgenic mice. We propose that these agents may serve as lead compounds for the development of anticancer drugs targeting Wip1 phosphatase.

[1]  Albert J. Fornace,et al.  Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity , 2002, Nature Genetics.

[2]  Dirk Strumberg,et al.  Raf Kinase Inhibitors in Oncology , 2005, Oncology Research and Treatment.

[3]  F. Uckun,et al.  Recent advances in JAK3 kinase inhibitors. , 1999, IDrugs : the investigational drugs journal.

[4]  L. Donehower,et al.  Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK–mediated activation of the p16Ink4a-p19Arf pathway , 2004, Nature Genetics.

[5]  Nobuyuki Tanaka,et al.  Mechanism of p38 MAP kinase activation in vivo. , 2003, Genes & development.

[6]  D. Fabbro,et al.  Targeting protein kinases in cancer therapy: a success? , 2004, Expert review of anticancer therapy.

[7]  J. Inazawa,et al.  Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  A. Fornace,et al.  p38 MAP kinase's emerging role as a tumor suppressor. , 2004, Advances in cancer research.

[9]  Jeffrey R. Marks,et al.  Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23 , 2002, Nature Genetics.

[10]  K. Sakaguchi,et al.  Phosphorylation of human p53 by p38 kinase coordinates N‐terminal phosphorylation and apoptosis in response to UV radiation , 1999, The EMBO journal.

[11]  S. Durell,et al.  Substrate specificity of the human protein phosphatase 2Cdelta, Wip1. , 2005, Biochemistry.

[12]  M. Fiscella,et al.  Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Jing Li,et al.  Wip1-deficient mice are resistant to common cancer genes. , 2004, Trends in molecular medicine.

[14]  Akira Nakagawara,et al.  PPM1D is a potential target for 17q gain in neuroblastoma. , 2003, Cancer research.

[15]  R. Bernards.  Wip-ing out cancer , 2004, Nature Genetics.

[16]  Masaaki Adachi,et al.  p53‐inducible Wip1 phosphatase mediates a negative feedback regulation of p38 MAPK‐p53 signaling in response to UV radiation , 2000, The EMBO journal.